EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes

Riccardo Candido, Barbara Toffoli, Gabriele Baccichetto, Francesca Marchese, Silvia Carpenè, Sara Gaiotti, Bruno Fabris, Stella Bernardi

Acta Diabetologica · 27.11.2025 · 63 (2) · 303-311

DOI: 10.1007/s00592-025-02626-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Diabetologica, online erschienen am 27.11.2025. Verfasst von Riccardo Candido und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Surgical and Health Sciences, University of Trieste, Cattinara Teaching Hospital, Strada di Fiume 447, 34149, Trieste, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glucagon-Like Peptide-1 Receptor, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Trieste.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Glucagon-like peptide-1 receptor (GLP-1R) has become one of the most promising ligand-receptor systems to target for type 2 diabetes mellitus (T2DM) treatment. Over the last two decades, several GLP-1 receptor agonists (GLP-1RAs) have been developed and semaglutide is the first and only GLP-1RA available as an oral formulation . GLP1R single nucleotide polymorphisms may affect GLP-1R response to oral semaglutide. Here we aimed to evaluate the impact of rs6923761 and rs761387 GLP1R polymorphisms on the response to oral semaglutide.

Methods

This is a retrospective cohort study including adult patients with T2DM who had been treated with oral semaglutide for at least one year. Patients were enrolled between November 2023 and April 2024, and then genotyped.

Results

We selected 210 adult patients with a median age of 71 years. Their median BMI was 29.1 kg/m 2 , HbA1c was 7.2% (55 mmol/mol), duration of diabetes was 12 years. After a median follow-up of 18 months, oral semaglutide reduced HbA1c by −0.3% (−3 mmol/mol), BMI by −1.1 kg/m2, SBP by −5 mmHg, total cholesterol by -8 mg/dL, triglycerides by -6.5 mg/dL. In addition, a reduction of ACR by −44.02 mg/g was observed in patients with baseline ACR > 30 mg/g, along with a decrease of liver transaminases in patients with baseline levels ≥ 35 U/L. Multivariate linear regression did not show any significant association between rs6923761 or rs761387 GLP1R genotypes and changes in HbA1c, BMI, SBP and DBP.

Conclusions

Our findings confirm the effectiveness of oral semaglutide in improving metabolic control and providing cardiorenal protection in different clinical scenarios. Conversely, they fail to show a clear benefit of GLP1R genotyping to guide treatment decisions, at least in patients with HbA1c < 7.5% (< 58 mmol/mol). Further studies are needed to confirm and extend our findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesGlucagon-Like Peptide-1 ReceptorPolymorphism, Single NucleotideHypoglycemic AgentsHumansSemaglutideFemaleMaleAgedMiddle AgedRetrospective StudiesAdministration, OralGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinBlood GlucoseGenotype

Stichwörter der Autor:innen

rs6923761rs761387GLP1ROral semaglutidePolymorphismType 2 diabetes

Substanzen

SemaglutideGlucagon-Like PeptidesGlucagon-Like Peptide-1 ReceptorGLP1R protein, humanHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinBlood Glucose

Autor:innen und Institutionen

  • Department of Medical Surgical and Health Sciences, University of Trieste, Cattinara Teaching Hospital, Strada di Fiume 447, 34149, Trieste, Italy.
  • SC Patologie Diabetiche, ASUGI (Azienda Sanitaria Universitaria Giuliano Isontina), Via Sai 7, 34128, Trieste, Italy.
  • SS Endocrinologia (Medicina Clinica), ASUGI (Azienda Sanitaria Universitaria Giuliano Isontina), Cattinara Teaching Hospital, Strada di Fiume 447, 34149, Trieste, Italy.
  • Department of Medical Surgical and Health Sciences, University of Trieste, Cattinara Teaching Hospital, Strada di Fiume 447, 34149, Trieste, Italy. stella.bernardi@units.it.
  • SS Endocrinologia (Medicina Clinica), ASUGI (Azienda Sanitaria Universitaria Giuliano Isontina), Cattinara Teaching Hospital, Strada di Fiume 447, 34149, Trieste, Italy. stella.bernardi@units.it.

Förderung

  • Università degli Studi di Trieste

Zitieren

APA

Candido, R., Toffoli, B., Baccichetto, G., Marchese, F., Carpenè, S., Gaiotti, S., Fabris, B., & Bernardi, S. (2025). Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes. Acta Diabetologica, 63(2), 303-311. https://doi.org/10.1007/s00592-025-02626-9

Vancouver

Candido R, Toffoli B, Baccichetto G, Marchese F, Carpenè S, Gaiotti S, et al. Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes. Acta Diabetologica. 2025;63(2):303-311. doi:10.1007/s00592-025-02626-9

BibTeX
@article{Candido2025,
  author = {Candido, Riccardo and Toffoli, Barbara and Baccichetto, Gabriele and Marchese, Francesca and Carpenè, Silvia and Gaiotti, Sara and Fabris, Bruno and Bernardi, Stella},
  title = {Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes},
  journal = {Acta Diabetologica},
  year = {2025},
  volume = {63},
  number = {2},
  pages = {303--311},
  doi = {10.1007/s00592-025-02626-9}
}
Kostenlos starten →